Comparison of Simple Models of Periodic Protocols for Combined Anticancer Therapy

Table 1

Results from clinical trials of single chemotherapy or combined with an antiangiogenic agent.

ClinicalTrials.gov identifier	Antiangiogenic agents	Cytostatic agents	Progression-free survival
NCT00219557	Axitinib	Gemcitabine; Gemcitabine	116 days (109 to 160); 113 days (68 to 205)
NCT00532155	Aflibercept	Docetaxel; Docetaxel	5.19 months (4.37 to 5.55); 4.11 months (3.52 to 4.34)
NCT00434252	Bevacizumab	Carboplatin, Paclitaxel; Carboplatin, Paclitaxel	5.6 months (4.21 to 6.80); 4.2 months (2.83 to 5.36)
NCT00687297	Vandetanib; 4 cycles and maintenance treatment	Docetaxel, Carboplatin	4.5 months (3.3 to 5.8)
	Vandetanib; 4 cycles only, no maintenance treatment	Docetaxel, Carboplatin	4.2 months (2.8 to 4.9)
NCT00130728	Erlotinib, Bevacizumab		3.4 months (2.79 to 4.27)
	Bevacizumab		1.7 months (1.48 to 2.53)